Previous Article |
Table of Contents
| Next Article
BIOLOGICAL SCIENCES / MICROBIOLOGY
Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharide



*Groupe de Génétique des Biofilms, Centre National de la Recherche Scientifique (CNRS), Unité de Recherche Associée 2172, and
Unité des Aspergillus, Institut Pasteur, 25 Rue du Dr. Roux, 75724 Paris Cedex 15, France;
Laboratoire Physico Chimie Curie, CNRS, Unité Mixte de Recherche 168, 11 Rue Pierre et Marie Curie, 75231 Paris Cedex 05, France; and
Laboratoire de Bactériologie, Faculté de Pharmacie, Université dAuvergne, 28 Place Henri Dunant, 63001 Clermont-Ferrand, France
Communicated by Jonathan Beckwith, Harvard Medical School, Boston, MA, June 28, 2006 (received for review April 28, 2006)
The development of surface-attached biofilm bacterial communities is considered an important source of nosocomial infections. Recently, bacterial interference via signaling molecules and surface active compounds was shown to antagonize biofilm formation, suggesting that nonantibiotic molecules produced during competitive interactions between bacteria could be used for biofilm reduction. Hence, a better understanding of commensal/pathogen interactions within bacterial community could lead to an improved control of exogenous pathogens. To reveal adhesion or growth-related bacterial interference, we investigated interactions between uropathogenic and commensal Escherichia coli in mixed in vitro biofilms. We demonstrate here that the uropathogenic strain CFT073 and all E. coli expressing group II capsules release into their environment a soluble polysaccharide that induces physicochemical surface alterations, which prevent biofilm formation by a wide range of Gram-positive and Gram-negative bacteria. We show that the treatment of abiotic surfaces with group II capsular polysaccharides drastically reduces both initial adhesion and biofilm development by important nosocomial pathogens. These findings identify capsular polymers as antiadhesion bacterial interference molecules, which may prove to be of significance in the design of new strategies to limit biofilm formation on medical in dwelling devices.
bacterial interference | Escherichia coli | group II capsule | extraintestinal
Conflict of interest statement: No conflicts declared.
¶To whom correspondence should be addressed. E-mail: jmghigo{at}pasteur.fr
© 2006 by The National Academy of Sciences of the USA
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg What's this?
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
C.-L. Y. Ong, G. C. Ulett, A. N. Mabbett, S. A. Beatson, R. I. Webb, W. Monaghan, G. R. Nimmo, D. F. Looke, A. G. McEwan, and M. A. Schembri Identification of Type 3 Fimbriae in Uropathogenic Escherichia coli Reveals a Role in Biofilm Formation J. Bacteriol., February 1, 2008; 190(3): 1054 - 1063. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Valle, S. Da Re, S. Schmid, D. Skurnik, R. D'Ari, and J.-M. Ghigo The Amino Acid Valine Is Secreted in Continuous-Flow Bacterial Biofilms J. Bacteriol., January 1, 2008; 190(1): 264 - 274. [Abstract] [Full Text] [PDF] |
||||